Low levels of S-adenosylmethionine have been found in people with liver conditions (nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, cirrhosis, etc.),[1][2][3] chronic kidney disease (CKD),[4] coronary artery disease (CAD),[5][6] depression,[7][8][9] and some neurodegenerative conditions like dementia and Alzheimer’s disease.[9][10] These observations suggest that supplementation could help treat such conditions. However, while S-adenosylmethionine has shown therapeutic effects in cell-culture experiments and animal models,[1][2][11] its therapeutic benefit in humans is less convincing.
Current evidence shows that S-adenosylmethionine might help treat depression[12][13][14][15] and might improve liver health and survival in people with liver conditions like cirrhosis.[16][17][18] However, due to the low quality of evidence, further large, double-blind randomized controlled trials are needed to clarify the clinical efficacy of S-adenosylmethionine.